Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.
